@article{e981fe5d836c4475adfe4eeeffe573e1,
title = "Passing the Kool-Aid Point: mRNA Expression–Based Risk Classifiers in Localized Prostate Cancer Treatment Decision Making",
author = "Desai, {Neil B.} and {Dal Pra}, Alan and Chua, {Melvin L.K.} and Alejandro Berlin",
note = "Funding Information: Disclosures: N.B.D. receives clinical research funding and consulting work from Boston Scientific. A.B. and N.B.D. co-lead a cooperative group study using a genomic biomarker (Decipher) noted in this article without financial relationship; the study is partially funded by Veracyte and Bayer. A.D.P. reports research support from Veracyte and an advisory board role with Merck and Pfizer. M.L.K.C. reports consulting or speaker honoraria from MSD, Immunoscape, IQVIA, Tellix, BeiGene, Astellas, AstraZeneca, Bayer, Janssen, Pfizer, Varian, Decipher Biosciences, and MedLever and stock ownership in Digital Life Line. ",
year = "2023",
month = jul,
day = "1",
doi = "10.1016/j.ijrobp.2022.12.002",
language = "English (US)",
volume = "116",
pages = "530--532",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",
}